Hederagenin is a Highly Selective Antagonist of the Neuropeptide FF Receptor 1 that Reveals Mechanisms for Subtype Selectivity
Authors:
Open Access
- 9 December 2024
- journal article
- Published by Wiley in Angewandte Chemie
- Vol. 137 (6)
Abstract
RF‐amide peptide receptors including the neuropeptide FF receptor 1 (NPFFR1) are G protein‐coupled receptors (GPCRs) that modulate diverse physiological functions. High conservation of endogenous ligands and receptors makes the identification of selective ligands challenging. Previously identified antagonists mimic the C‐terminus of peptide ligands and lack selectivity towards the closely related neuropeptide FF receptor 2 (NPFFR2) or the neuropeptide Y1 receptor (Y1R). In a high‐throughput screening, we identified the pentacyclic triterpenoid hederagenin (1) as a novel selective antagonist for the NPFFR1. Hederagenin (1) is a natural product isolated from Hedera helix (ivy). We characterized its mode of activity using in vitro and in silico methods, revealing an overlapping binding site of the small molecule with the orthosteric peptide agonists. Despite the high similarity of the orthosteric binding pockets of NPFFR1 and NPFFR2, hederagenin (1) shows strong subtype selectivity, particularly caused by slight differences in the shape of the binding pockets and the rigidity of the small molecule. Several residues inhibiting the activity of hederagenin (1) at the NPFFR2 were identified. As NPFFR1 antagonists are discussed as potential candidates for the treatment of chronic pain, these insights into the structural determinants governing subtype specificity will facilitate the development of next‐generation analgesics with improved safety and efficacy.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (421152132, SFB1423 B01, 421152132, SFB1423 A07 and Z04, 209933838 SFB1052,C08)
- National Institutes of Health (R01 DA046138)
- National Science Foundation (T32 DK101003)
This publication has 49 references indexed in Scilit:
- UniProt Tools: BLAST, Align, Peptide Search, and ID MappingCurrent Protocols, 2023
- Multi‐state modeling of G‐protein coupled receptors at experimental accuracyProteins: Structure, Function, and Bioinformatics, 2022
- Orthosteric Drug Antagonism2019
- Position and Length of Fatty Acids Strongly Affect Receptor Selectivity Pattern of Human Pancreatic Polypeptide AnaloguesChemMedChem, 2014
- Rosetta Ligand Docking with Flexible XML Protocols2011
- Structure–Activity Studies of RFamide Peptides Reveal Subtype‐Selective Activation of Neuropeptide FF1 and FF2 ReceptorsChemMedChem, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- ROSETTALIGAND: Protein–small molecule docking with full side‐chain flexibilityProteins: Structure, Function, and Bioinformatics, 2006
- Evolution of neuropeptide Y, peptide YY and pancreatic polypeptideRegulatory Peptides, 1996
- The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226European Journal of Pharmacology, 1994